Astrazeneca Pharma India Ltd

Astrazeneca Phar Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Astrazeneca Pharma India Ltd

₹ 10,054 -0.02%
10 Jun - close price
astrazenecaindia.com BSE: 506820 NSE: ASTRAZEN
About

AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]

Key Points

Part of AstraZeneca UK plc
The company is promoted by AstraZeneca plc, a multinational pharmaceutical and biotechnology company headquartered in England. It has a diverse portfolio in various disease areas and has been successful in developing and manufacturing the Oxford-AstraZeneca COVID-19 vaccine. AstraZeneca Pharmaceuticals AB holds 75% of the company's shareholding.[1] [2]

Website BSE NSE
  • Market Cap ₹ 25,136 Cr.
  • Current Price ₹ 10,054
  • High / Low ₹ 10,145 / 6,070
  • Stock P/E 144
  • Book Value ₹ 308
  • Dividend Yield 0.24 %
  • ROCE 33.4 %
  • ROE 23.6 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 19.4% CAGR over last 5 years

Cons

  • Stock is trading at 32.6 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
232 232 236 250 285 295 311 306 383 388 408 440 480
194 204 195 213 225 228 258 291 334 349 355 363 394
Operating Profit 38 28 41 37 60 67 53 15 49 38 53 77 86
OPM % 16% 12% 17% 15% 21% 23% 17% 5% 13% 10% 13% 17% 18%
4 4 7 7 -32 8 25 10 9 -49 8 -26 10
Interest 0 0 0 0 0 0 0 1 -0 0 0 0 1
Depreciation 4 5 3 4 4 4 4 4 4 4 9 9 18
Profit before tax 37 27 44 39 23 71 73 20 54 -15 51 42 78
Tax % 24% 26% 26% 26% 26% 25% 29% 23% 27% -22% 25% 27% 26%
28 20 33 29 17 54 52 16 39 -12 38 31 58
EPS in Rs 11.19 8.06 13.02 11.72 6.91 21.54 20.95 6.32 15.79 -4.72 15.37 12.34 23.30
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
474 517 564 544 571 728 832 814 806 1,003 1,296 1,716
487 528 547 506 525 657 711 678 719 838 1,111 1,462
Operating Profit -13 -11 16 37 46 71 121 135 86 165 184 254
OPM % -3% -2% 3% 7% 8% 10% 15% 17% 11% 16% 14% 15%
23 6 7 14 12 16 13 13 15 -14 51 -56
Interest 0 0 0 0 0 0 1 1 1 1 1 1
Depreciation 10 15 17 16 15 15 19 20 17 16 15 40
Profit before tax 0 -21 6 36 44 73 114 127 83 134 220 156
Tax % 0% 9% 44% 41% 25% 37% 27% 26% 26% 26% 26%
-1 -21 5 20 26 54 72 93 62 99 162 116
EPS in Rs -0.20 -8.34 2.10 8.02 10.36 21.78 28.88 37.32 24.64 39.72 64.60 46.30
Dividend Payout % 0% 0% 0% 0% 0% 0% 3% 5% 41% 40% 37% 0%
Compounded Sales Growth
10 Years: 13%
5 Years: 16%
3 Years: 29%
TTM: 32%
Compounded Profit Growth
10 Years: 26%
5 Years: 19%
3 Years: 43%
TTM: 17%
Stock Price CAGR
10 Years: 25%
5 Years: 26%
3 Years: 51%
1 Year: 59%
Return on Equity
10 Years: 19%
5 Years: 21%
3 Years: 23%
Last Year: 24%

Balance Sheet

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 5 5 5 5 5 5 5 5 5 5 5 5
Reserves 167 146 151 218 242 296 359 451 506 584 707 765
0 0 0 0 0 0 12 12 9 7 5 36
244 261 247 193 214 261 330 306 337 389 362 712
Total Liabilities 416 412 403 415 461 562 706 775 857 985 1,078 1,518
94 101 97 87 75 75 72 81 74 69 67 64
CWIP 9 12 6 5 4 7 24 4 2 1 0 0
Investments 0 0 0 0 0 0 0 0 0 0 0 0
312 298 299 324 382 480 611 690 780 915 1,011 1,454
Total Assets 416 412 403 415 461 562 706 775 857 985 1,078 1,518

Cash Flows

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
-1 -46 57 38 9 55 87 105 101 58 28 65
-15 -19 -4 0 -9 4 -171 173 5 18 22 31
86 0 -1 0 0 0 -6 -9 -9 -24 -44 -66
Net Cash Flow 71 -64 53 38 -1 59 -90 269 96 52 5 31

Ratios

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 41 30 54 29 35 40 37 38 39 39 43 39
Inventory Days 210 157 141 121 229 186 197 198 164 193 140 208
Days Payable 241 203 174 184 257 266 251 221 223 231 121 173
Cash Conversion Cycle 10 -16 21 -34 7 -39 -17 15 -20 1 62 74
Working Capital Days -45 -15 -28 -36 -8 -14 -15 -15 -33 -17 20 23
ROCE % -12% -13% 4% 15% 19% 27% 34% 30% 16% 31% 31% 33%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00%
2.48% 2.49% 2.61% 2.70% 2.68% 2.69% 2.66% 2.73% 2.79% 2.90% 2.92% 2.89%
1.30% 1.32% 1.42% 1.41% 1.91% 2.42% 2.76% 3.77% 4.99% 5.08% 5.21% 4.65%
21.22% 21.19% 20.97% 20.88% 20.40% 19.89% 19.57% 18.50% 17.21% 17.02% 16.85% 17.45%
No. of Shareholders 53,98049,08545,61942,14638,94632,38029,03229,41827,16927,61527,32232,466

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls